# A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

> **NCT05856526** · PHASE2,PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 43 (actual)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** Spesolimab - solution for infusion
- **DRUG:** Placebo matching to spesolimab - solution for infusion
- **DRUG:** Spesolimab - solution for injection
- **DRUG:** Placebo matching to spesolimab - solution for injection

## Key facts

- **NCT ID:** NCT05856526
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-12
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-07-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856526, "A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05856526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*